242 related articles for article (PubMed ID: 19941237)
1. [Management of Graves' orbitopathy: evidence-based recommendations].
Ponto KA; Pitz S; Mann WJ; Weber MM; Pfeiffer N; Kahaly GJ
Dtsch Med Wochenschr; 2009 Dec; 134(49):2521-4. PubMed ID: 19941237
[TBL] [Abstract][Full Text] [Related]
2. Update on the surgical management of Graves' orbitopathy.
Baeg J; Choi HS; Kim C; Kim H; Jang SY
Front Endocrinol (Lausanne); 2022; 13():1080204. PubMed ID: 36824601
[TBL] [Abstract][Full Text] [Related]
3. Presentation of Graves' orbitopathy within European Group On Graves' Orbitopathy (EUGOGO) centres from 2012 to 2019 (PREGO III).
Schuh A; Ayvaz G; Baldeschi L; Baretić M; Bechtold D; Boschi A; Brix TH; Burlacu MC; Ciric J; Covelli D; Currò N; Donati S; Eckstein AK; Fichter N; Führer D; Horn M; Jabłońska-Pawlak A; Juri Mandić J; Kahaly GJ; Konuk O; Langbein A; Lanzolla G; Marcocci C; Marinò M; Miśkiewicz P; Beleslin BN; Pérez-Lázaro A; Pérez-López M; Ponto KA; Quinn A; Rudofsky G; Salvi M; Schittkowski MP; Tanda ML; Toruner F; Vaidya B; Hintschich CR
Br J Ophthalmol; 2024 Jan; 108(2):294-300. PubMed ID: 36627174
[TBL] [Abstract][Full Text] [Related]
4. Management of patients with Graves' orbitopathy: initial assessment, management outside specialised centres and referral pathways.
Perros P; Dayan CM; Dickinson AJ; Ezra D; Estcourt S; Foley P; Hickey J; Lazarus JH; MacEwen CJ; McLaren J; Rose GE; Uddin J; Vaidya B
Clin Med (Lond); 2015 Apr; 15(2):173-8. PubMed ID: 25824071
[TBL] [Abstract][Full Text] [Related]
5. Risk Factors for Ocular Surface Irritation Symptoms in Inactive Mild and Moderate-to-Severe Graves' Orbitopathy.
Yu Y; Hu YX; Lu MX; Ouyang ZL; Xu MT; Zhao LY; Wang M
Ophthalmol Ther; 2024 Apr; 13(4):1015-1024. PubMed ID: 38376797
[TBL] [Abstract][Full Text] [Related]
6. Statins in Graves Orbitopathy: A New Therapeutic Tool.
Lanzolla G; Comi S; Cosentino G; Pakdel F; Marinò M
Ophthalmic Plast Reconstr Surg; 2023 Dec; 39(6S):S29-S39. PubMed ID: 38054983
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of rituximab in treating steroid-resistant Graves' orbitopathy in active moderate-to-severe and sight-threatening forms: A retrospective observation from China.
Zhang Z; Feng X; Guo Y; Kang X; Wang D; Zhang J; Zeng Z; Yuan G
Heliyon; 2024 Jun; 10(11):e31932. PubMed ID: 38867959
[TBL] [Abstract][Full Text] [Related]
8. [Endocrine orbitopathy].
Mühl-Benninghaus R
Radiologie (Heidelb); 2024 Mar; 64(3):215-218. PubMed ID: 38321288
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of disease-specific quality of life and its influencing factors in Bulgarian patients with Graves' orbitopathy.
Stoynova MA; Shinkov AD; Dimitrova ID; Yankova IA; Kovatcheva RD
Int Ophthalmol; 2024 Feb; 44(1):68. PubMed ID: 38347322
[TBL] [Abstract][Full Text] [Related]
10. Current Knowledge on Graves' Orbitopathy.
Gontarz-Nowak K; Szychlińska M; Matuszewski W; Stefanowicz-Rutkowska M; Bandurska-Stankiewicz E
J Clin Med; 2020 Dec; 10(1):. PubMed ID: 33374706
[TBL] [Abstract][Full Text] [Related]
11. Key data from the 2023 European Thyroid Association congress: Breakthrough advances in the treatment of Graves' orbitopathy.
Ladsous M; Caron P
Ann Endocrinol (Paris); 2024 Apr; 85(2):150-151. PubMed ID: 38307804
[No Abstract] [Full Text] [Related]
12. Medical and surgical treatment of thyroid eye disease.
Hall AJH; Topliss DJ
Intern Med J; 2022 Jan; 52(1):14-20. PubMed ID: 32975863
[TBL] [Abstract][Full Text] [Related]
13. A rare case of severe bilateral Graves' orbitopathy involving an anophthalmic socket.
Ali M; Abouzaid M; Clarke L; Lau G; Mitchell A; Napier C; Pearce S
Endocrinol Diabetes Metab Case Rep; 2023 Jan; 2023(1):. PubMed ID: 36625261
[TBL] [Abstract][Full Text] [Related]
14. Understanding the clinical and molecular basis of thyroid orbitopathy: a review of recent evidence.
Nivean PD; Madhivanan N; Kumaramanikavel G; Berendschot TTJM; Webers CAB; Paridaens D
Hormones (Athens); 2024 Mar; 23(1):25-34. PubMed ID: 37910311
[TBL] [Abstract][Full Text] [Related]
15. Glucocorticoid-induced adrenal insufficiency after therapy with intravenous methylprednisolone in patients with moderate-to-severe and active Graves' orbitopathy: assessment with a low-dose corticotropin test.
Pelewicz K; Miśkiewicz P
J Endocrinol Invest; 2024 Feb; ():. PubMed ID: 38310626
[TBL] [Abstract][Full Text] [Related]
16. The key data from the 2022 European Thyroid Association congress: Toward personalized treatment of Graves' orbitopathy.
Abeillon-du Payrat J; Caron P
Ann Endocrinol (Paris); 2023 Dec; 84(6):756-757. PubMed ID: 37285956
[No Abstract] [Full Text] [Related]
17. Late orbital radiotherapy combined with intravenous methylprednisolone in the management of long-lasting active graves' orbitopathy: a case report and literature review.
Verrienti M; Gagliardi I; Valente L; Stefanelli A; Borgatti L; Franco E; Galiè M; Bondanelli M; Zatelli MC; Ambrosio MR
Endocrine; 2024 Mar; ():. PubMed ID: 38517640
[TBL] [Abstract][Full Text] [Related]
18. [Four perspectives on Graves' orbitopathy - from the point of view of the patient, general practitioner, endocrinologist, and ophthalmologist].
Filipsson Nyström H; Fellbrant K; Lundberg C; Botusan I; Åsman P; Träisk F
Lakartidningen; 2024 May; 121():. PubMed ID: 38775447
[TBL] [Abstract][Full Text] [Related]
19. Analysis of the Impact of Ambulatory Care Based on Social Support on the Quality of Life of Patients with Graves' Ophthalmopathy.
Sun R; Li J; Li Y; Liu W; Xing L; Zhang J
Altern Ther Health Med; 2024 Jun; ():. PubMed ID: 38843425
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
